NCT06604780 (PPREINGRESOS) is a NA clinical trial of Transitional discharge program in Readmission, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud.

What drugs are being tested in NCT06604780?

Interventions in NCT06604780: Transitional discharge program.

What condition does NCT06604780 study?

NCT06604780 studies Readmission, Mental Health Disorder, Hospitalizations Psychiatric.

Is NCT06604780 still recruiting?

NCT06604780 is currently recruiting now. Last updated 20 September 2024.

Last reviewed 2024-09-20 · How we verify

NCT06604780: PPREINGRESOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Early Readmission to an Acute Psychiatric Unit

Recruiting now NA Last updated 20 September 2024

What this trial tests

NA trial testing Transitional discharge program in Readmission in 836 participants. Currently enrolling.

Timeline

1 January 2023

Primary endpoint
30 March 2024

30 March 2025

Quick facts

Lead sponsor	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	836
Start date	1 January 2023
Primary completion	30 March 2024
Estimated completion	30 March 2025
Sites	1 location across Spain

Drugs / interventions tested

Transitional discharge program

Conditions studied

Readmission — all drugs for Readmission →
Mental Health Disorder — all drugs for Mental Health Disorder →
Hospitalizations Psychiatric — all drugs for Hospitalizations Psychiatric →

Sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — full company profile →

Who can join

18 and older, any sex, with Readmission or Mental Health Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early readmission to psychiatric units poses a significant challenge for both patients with mental health issues and healthcare institutions. It hampers patient progress and prognosis, and the professional approach taken during discharge can greatly influence the recovery process. This paper proposes a multicomponent discharge transition intervention to mitigate the risk of early readmission to a Mental Health Hospitalization Unit (MHHU). The intervention entails developing a measurement scale to assess patients' risk of early readmission, allowing for stratification into high, medium, and low-risk categories. Tailored intervention strategies will focus on ensuring adherence and continuity of care post-discharge, with a more comprehensive approach for high-risk patients. Additionally, a post-discharge psychotherapeutic group will be incorporated for high-risk cases to support recovery. The efficacy of the program will be analyzed by comparing the overall early readmission risk at the Regional Hospital of Malaga's MHHU with the previous year, using admission episodes from two other hospitals in the province as a control group where the intervention program is not implemented. The success of the post-discharge group psychotherapeutic intervention will be evaluated through pre-post assessments of recovery measures, functionality, subjective well-being, social support, and treatment satisfaction. This proposal aims to address the issue of early readmission to psychiatric units by enhancing predictability and understanding of intervention strategies to reduce readmission rates.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Design and predictive performance analysis of an early readmission risk index in a mental health hospitalization unit: an exploratory study.
García-Illanes Y, Carbonell-Aranda V, Traverso-Rodriguez M, Pérez-Guerrero G, et al · · 2026 · PMID 42111567 · DOI 10.3389/fpsyg.2026.1776125

Verify or expand the search:

Other Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud trials

Trials by the same sponsor.

NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticod · NA · recruiting
NCT06936501 — The Cooling Sensation Safe Deglution Study · NA · recruiting
NCT07192445 — Usability of Graphic Medicine in Psychology Education · NA · completed
NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting
NCT06251232 — Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06604780 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Last refreshed: 20 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06604780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing